Unity Biotechnology Future Growth
Future criteria checks 0/6
Unity Biotechnology is forecast to grow earnings and revenue by 23.3% and 61.3% per annum respectively. EPS is expected to grow by 27.5% per annum. Return on equity is forecast to be -580.4% in 3 years.
Key information
23.3%
Earnings growth rate
27.5%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 61.3% |
Future return on equity | -580.4% |
Analyst coverage | Low |
Last updated | 16 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 14 | -28 | N/A | N/A | 2 |
12/31/2025 | N/A | -37 | N/A | N/A | 3 |
12/31/2024 | N/A | -41 | N/A | N/A | 3 |
12/31/2023 | N/A | -40 | -37 | -37 | N/A |
9/30/2023 | N/A | -53 | -40 | -40 | N/A |
6/30/2023 | N/A | -51 | -44 | -44 | N/A |
3/31/2023 | 0 | -52 | -47 | -47 | N/A |
12/31/2022 | 0 | -44 | -53 | -52 | N/A |
9/30/2022 | 5 | -56 | -46 | -46 | N/A |
6/30/2022 | 5 | -59 | -47 | -46 | N/A |
3/31/2022 | 5 | -64 | -45 | -45 | N/A |
12/31/2021 | 5 | -61 | -45 | -45 | N/A |
9/30/2021 | N/A | -70 | -57 | -57 | N/A |
6/30/2021 | N/A | -81 | -63 | -62 | N/A |
3/31/2021 | N/A | -82 | -69 | -68 | N/A |
12/31/2020 | N/A | -94 | -79 | -78 | N/A |
9/30/2020 | N/A | -92 | -78 | -77 | N/A |
6/30/2020 | N/A | -86 | -78 | -77 | N/A |
3/31/2020 | N/A | -91 | -78 | -77 | N/A |
12/31/2019 | N/A | -82 | -74 | -72 | N/A |
9/30/2019 | N/A | -86 | -71 | -70 | N/A |
6/30/2019 | N/A | -83 | -68 | -67 | N/A |
3/31/2019 | N/A | -79 | -67 | -65 | N/A |
12/31/2018 | N/A | -76 | -58 | -57 | N/A |
9/30/2018 | 1 | -67 | -57 | -55 | N/A |
6/30/2018 | 1 | -60 | -52 | -51 | N/A |
3/31/2018 | 1 | -52 | -44 | -42 | N/A |
12/31/2017 | 1 | -45 | -40 | -38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9U9 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9U9 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9U9 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9U9 is forecast to have no revenue next year.
High Growth Revenue: 9U9 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9U9 is forecast to be unprofitable in 3 years.